Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated anti-addictive properties; however, their impact on smoking behaviors remains under-researched. This review provides a synthesis of the therapeutic potential of these compounds in promoting smoking cessation and reduction. Methods: A systematic...
Methamphetamine use disorder, associated with significant morbidity and mortality, has limited effective treatments. Psychedelic-assisted psychotherapy shows promise, but data on its safety and efficacy in this population are limited. This exploratory study describes the demographic, substance use, and mental health characteristics of people who used methamphetamine and psychedelics and the...
Ketamine, originally developed as an anesthetic, is gaining increasing attention due to its multifaceted pharmacological properties. In addition to its use in anesthesia, ketamine exerts potent analgesic effects via N-methyl-D-aspartate (NMDA) receptor antagonism, modulating pain perception and reducing central sensitization, particularly in chronic and neuropathic pain conditions. Emerging...
bioRxiv Preprint ServerJune 24, 2025Marco German Ghilotti, Ricardo Petrilli Fortuna, Kofi Osei-Abrefa Ayensu et al.
preprint
Background The use of methamphetamine has continued to rise in the US. In addition to facilitating dopamine neurotransmission, methamphetamine indirectly increases glutamate release which activates N-methyl-D-aspartate receptors (NMDARs). Ketamine is a noncompetitive NMDAR antagonist. Ketamine also has actions on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and...
Professor Stephen Ross is a prominent faculty member in the Departments of Psychiatry and Child and Adolescent Psychiatry at the New York University (NYU) Grossman School of Medicine who has transformed the landscape of psychedelic research since 2006. In this Genomic Press Interview, Dr. Ross reveals how as co-director of the NYU Langone Center for Psychedelic Medicine and director of its...
Psychedelics may be promising treatments for substance use disorders (SUD). This study aims to understand how individuals with alcohol use disorder (AUD), opioid use disorder (OUD), and psychiatric disorders perceive and experience psychedelics for both nonmedical and medical use. Data for this cross-sectional survey study were collected from June 2023 to February 2024 at a large, tertiary...
Brain SciencesMay 26, 2025Charles Palmer, Ally T Ferber, Brian D Greenwald4 citations
Background: This narrative review explores psilocybin’s potential use as a therapeutic agent in patients with traumatic brain injury (TBI). Methods: We engaged in a search of PubMed, ScienceDirect, and Cochrane’s databases for information on the effects of psilocybin. We also reviewed articles where psilocybin was used in patients with TBI. Articles from 2000–2025 were included. Results: A...
CureusMay 1, 2025Alyssa Kong, Viseth Long, Elle Wang et al.
Introduction To address the rising deaths and hospitalizations related to opioid toxicity, buprenorphine/naloxone has been provided as a frontline treatment within the emergency department (ED), allowing increased access to opioid agonist therapies (OAT). However, several barriers exist toward initiating patients on buprenorphine/naloxone within the ED, such as shortages in healthcare staff and...
Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intensity and quality of psychedelic experiences plays a significant role in mediating therapeutic effects. However, the strength of this association across diagnoses and treatment settings remains underexplored. We searched MEDLINE, Embase, and PsycINFO...
To report the symptoms and aetiology of ketamine use disorder (KUD), gauge the effectiveness of current treatment services and identify strategies to enhance patient access and outcomes. Mixed-methods, cross-sectional questionnaire. Electronic survey from November 2023 to April 2024. Participants were recruited through snowball sampling, social media and referrals from UK addiction treatment...